Fax: (401) 444-5017
Percutaneous radiofrequency ablation of painful osseous metastases
A multicenter American College of Radiology Imaging Network trial
Version of Record online: 29 DEC 2009
Copyright © 2010 American Cancer Society
Volume 116, Issue 4, pages 989–997, 15 February 2010
How to Cite
Dupuy, D. E., Liu, D., Hartfeil, D., Hanna, L., Blume, J. D., Ahrar, K., Lopez, R., Safran, H. and DiPetrillo, T. (2010), Percutaneous radiofrequency ablation of painful osseous metastases. Cancer, 116: 989–997. doi: 10.1002/cncr.24837
- Issue online: 2 FEB 2010
- Version of Record online: 29 DEC 2009
- Manuscript Accepted: 15 JUN 2009
- Manuscript Revised: 4 JUN 2009
- Manuscript Received: 20 MAR 2009
- bone metastases;
- radiofrequency ablation;
- pain palliation;
- tumor ablation
The study was conducted to determine whether radiofrequency ablation (RFA) can safely reduce pain from osseous metastatic disease.
The single-arm prospective trial included patients with a single painful bone metastasis with unremitting pain with a score >50 on a pain scale of 0-100. Percutaneous computed tomography-guided RFA of the bone metastasis to temperatures >60°C was performed. Endpoints were the toxicity and pain effects of RFA before and at 2 weeks, 1 month, and 3 months after RFA.
Fifty-five patients completed RFA. Grade 3 toxicities occurred in 3 of 55 (5%) patients. RFA reduced pain at 1 and 3 months for all pain assessment measures. The average increase in pain relief from pre-RFA to 1-month follow-up is 26.3 (95% confidence interval [CI], 17.7-34.9; P < .0001), and the increase from pre-RFA to 3-month follow-up is 16.38 (95% CI, 3.4-29.4; P = .02). The average decrease in pain intensity from pre-RFA to 1-month follow-up was 26.9 (P < .0001) and 14.2 for 3-month follow-up (P = .02). The odds of lower pain severity at 1-month follow-up were 14.0 (95% CI, 2.3-25.7; P < .0001) times higher than at pre-RFA, and the odds at 3-month follow-up were 8.0 (95% CI, 0.9-15.2; P < .001) times higher than at pre-RFA. The average increase in mood from pre-RFA to 1-month follow-up was 19.9 (P < .0001) and 14.9 to 3-month follow-up (P = .005).
This cooperative group trial strongly suggests that RFA can safely palliate pain from bone metastases. Cancer 2010. © 2010 American Cancer Society